DHR Danaher Corporation - Fundamental Analysis
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Danaher trades at a steep valuation premium despite subpar ROE and revenue growth, especially when compared to higher-growth, higher-ROE peers like AMGN and BNTX.
- Forward P/E of 26.40 is more reasonable and in line with TMO (33.45) and below historical P/E
- Price/Sales of 6.44 reflects premium for recurring-revenue diagnostics model
- Current P/E of 45.42 is extremely high versus sector average of 26.61 and forward growth trajectory
- Price/Book of 3.06 lacks support from ROE of only 6.84% (sector avg: 25.21%)
While earnings momentum is positive and recent price action (6M +13.2%) reflects improving sentiment, the modest revenue trajectory and lack of earnings surprise history constrain forward multiple expansion.
- Earnings growth of 13.4% YoY outpaces revenue growth, suggesting margin expansion
- Q/Q earnings growth of 11.0% indicates sustained profitability momentum
- Revenue growth of 4.4% is below sector average of 10.85%, limiting scalability narrative
- No visibility into innovation pipeline or TAM expansion in Diagnostics & Research
Historical share price performance has been weak over 1Y and 3Y horizons despite stable margins, and the absence of earnings track record data undermines confidence in past execution quality.
- Consistent profitability with stable gross and operating margins over time
- Long-term shareholder base evidenced by low volatility in share count
- No quarterly earnings data available to assess beat/miss trend or consistency
- 1Y return of -7.0%, 3Y return of -6.3%, underperforming sector and peers like TMO (+8.9% 1Y)
Danaher’s conservative leverage profile provides resilience relative to highly leveraged peers like AMGN, though the weak quick ratio and missing cash flow data introduce uncertainty in stress scenarios.
- Low debt/equity ratio of 0.36, well below sector average of 1.62 and AMGN's 5.67
- Current ratio of 1.52 indicates adequate short-term liquidity
- Quick ratio of 0.83 suggests potential near-term liquidity pressure if receivables slow
- Missing total cash, debt, and cash flow data limits full solvency assessment
The dividend policy is conservative and sustainable, but the minimal yield and lack of growth history make it a secondary consideration for investors.
- Low payout ratio of 25.31% ensures high dividend sustainability
- Dividend yield of 0.58% reflects reinvestment focus over income orientation
- Yield is below sector average and peer group (e.g., AMGN yields ~3%)
- No 5-year yield history or growth trend available, limiting income appeal
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for DHR and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
DHR
Danaher Corporation
Primary
|
+11.0% | -6.3% | -7.0% | +13.2% | +7.3% | +5.4% |
|
BSX
Boston Scientific Corporation
Peer
|
+170.0% | +142.1% | +17.2% | -3.2% | +5.1% | +2.7% |
|
PFE
Pfizer Inc.
Peer
|
-9.7% | -38.6% | +3.3% | +13.6% | +4.6% | +2.6% |
|
SYK
Stryker Corporation
Peer
|
+61.8% | +68.1% | -4.6% | -7.7% | -2.0% | +1.7% |
|
AMGN
Amgen Inc.
Peer
|
+65.4% | +30.6% | +17.6% | +24.6% | +13.3% | +5.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
DHR
Danaher Corporation
|
NEUTRAL | $156.25B | 45.42 | 6.8% | 14.4% | $221.21 | |
|
BSX
Boston Scientific Corporation
|
BULLISH | $155.63B | 54.91 | 12.5% | 14.4% | $102.69 | |
|
PFE
Pfizer Inc.
|
NEUTRAL | $146.63B | 14.57 | 10.6% | 15.7% | $25.06 | |
|
SYK
Stryker Corporation
|
NEUTRAL | $142.8B | 47.6 | 14.0% | 12.1% | $362.22 | |
|
AMGN
Amgen Inc.
|
NEUTRAL | $181.33B | 26.02 | 81.7% | 19.5% | $336.74 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-12 | ELLIS BRIAN W | General Counsel | Sale | 21,776 | $4,773,863 |
| 2025-11-12 | RALES MITCHELL P | Officer and Director | Sale | 437,000 | $95,566,167 |
| 2025-11-12 | ELLIS BRIAN W | General Counsel | Option Exercise | 21,776 | $1,275,856 |
| 2025-11-11 | MCGREW MATTHEW | Chief Financial Officer | Sale | 16,172 | $3,470,831 |
| 2025-11-11 | MCGREW MATTHEW | Chief Financial Officer | Option Exercise | 16,172 | $1,016,410 |
| 2025-11-10 | COUCHARA GEORGEANN F. | Officer | Sale | 5,174 | $1,088,704 |
| 2025-11-10 | COUCHARA GEORGEANN F. | Officer | Option Exercise | 4,176 | $368,490 |
| 2025-10-31 | RALES MITCHELL P | Officer and Director | Sale | 600,000 | $129,636,027 |
| 2025-08-22 | LIST-STOLL TERI L. | Director | Sale | 2,778 | $586,319 |
| 2025-07-15 | ZERHOUNI ELIAS A | Director | Option Exercise | 3,928 | $233,088 |
| 2025-07-15 | SCHWIETERS JOHN T | Director | Option Exercise | 3,928 | $233,088 |
| 2025-07-02 | LIST-STOLL TERI L | Director | Option Exercise | 3,928 | $233,088 |
Wall Street Analysts
Professional analyst ratings and price targets